Veronica Mollica
University of Bologna
CancerInternal medicineRadiologyPathologyOncologyRandomized controlled trialAdverse effectHazard ratioRenal cell carcinomaImmunotherapyDiseaseSunitinibNivolumabPembrolizumabProstate cancerPopulationMetastatic Urothelial CarcinomaImmune checkpoint inhibitorsCancer researchClinical trialMedicineImmune systemMeta-analysis
98Publications
13H-index
389Citations
Publications 92
Newest
OBJECTIVE Recent years have registered the advent of novel treatment options for metastatic renal cell carcinoma (mRCC), including combination therapies with immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs). Immuno-TKI combinations have been suggested to improve clinical outcomes but may also result in increased toxicity, including gastrointestinal (GI) adverse events. METHODS Herein, we performed a meta-analysis aimed at comparing the risk of certain GI toxicities in mR...
Source
Non-clear cell renal cell carcinomas are a miscellaneous group of tumors that include different histological subtypes, each one characterized by peculiarity in terms of genetic alteration, clinical behavior, prognosis, and treatment response. Because of their low incidence and poor enrollment in clinical trials, alongside their heterogeneity, additional efforts are required to better unveil the pathogenetic mechanisms and, consequently, to improve the treatment algorithm. Nowadays, tyrosine kina...
Source
#1Alessandro RizzoH-Index: 14
#2Veronica MollicaH-Index: 13
Last. Francesco MassariH-Index: 41
view all 3 authors...
Source
INTRODUCTION Substantial paradigm shifts have been recently registered in metastatic renal cell carcinoma (mRCC), with combination therapies including immunotherapy showing unprecedented results. We performed number needed to treat (NNT) and number needed to harm (NNH) analyses to evaluate these approaches in mRCC. AREAS COVERED Clinical data of mRCC patients enrolled in four phase III trials were collected. The rates at 6, 12, 18, and 24 months for overall survival (OS), duration of response (D...
Source
Source
#1Sara Elena Rebuzzi (UniGe: University of Genoa)H-Index: 8
#2Alessio Signori (UniGe: University of Genoa)H-Index: 28
Last. Giuseppe FornariniH-Index: 20
view all 45 authors...
Background:Despite the survival advantage, not all metastatic renal cell carcinoma (mRCC) patients achieve a long-term benefit from immunotherapy. Moreover, the identification of prognostic biomark...
Source
#1Alessandro RizzoH-Index: 14
#2Veronica MollicaH-Index: 13
Last. Francesco MassariH-Index: 41
view all 3 authors...
Source
#1Alessandro RizzoH-Index: 14
#2Veronica MollicaH-Index: 13
Last. Francesco MassariH-Index: 41
view all 3 authors...
Source
#1Alessia Cimadamore (Marche Polytechnic University)H-Index: 17
#2Alessandro RizzoH-Index: 14
Last. Rodolfo Montironi (Marche Polytechnic University)H-Index: 96
view all 9 authors...
Source
#1Alessandro RizzoH-Index: 14
#2Veronica MollicaH-Index: 13
Last. Francesco MassariH-Index: 41
view all 11 authors...
Aim: Immune checkpoint inhibitor (ICI)-based combinations have become the new standard of primary systemic treatment for metastatic renal cell carcinoma patients. We performed a meta-analysis aimed at evaluating ICIs plus tyrosine kinase inhibitors (TKIs) combinations across International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk groups. Materials & methods: All the relevant randomized clinical trials were retrieved through Cochrane library, PubMed/Med and EMBASE; three Pha...
Source